High-level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patients

Histopathology

Volumn 58, Issue 5, 2011, Pages 781-789

  Fleischmann, Achim ^a   Rocha, Carla ^a   Saxer Sekulic, Nikolina ^a   Zlobec, Inti ^b   Sauter, Guido ^c   Thalmann, George N ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cyclin D1; Lymph node metastases; Prognosis; Prostate cancer

Indexed keywords

CYCLIN D1;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CELLULAR DISTRIBUTION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; SURGICAL PATIENT;

CYCLIN D1; CYTOPLASM; DISEASE-FREE SURVIVAL; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 79954572533     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03800.x     Document Type: Article

References (50)

1. Gladden AB, Diehl JA. Location, location, location: the role of cyclin D1 nuclear localization in cancer. J. Cell. Biochem. 2005; 96; 906-913.
2. Alt JR, Cleveland JL, Hannink M, Diehl JA. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 2000; 14; 3102-3114.
3. De Falco M, Fedele V, De Luca L et al. Evaluation of cyclin D1 expression and its subcellular distribution in mouse tissues. J. Anat. 2004; 205; 405-412.
4. Kaplan D, Meyerson H, Husel W, Lewandowska K, MacLennan G. D cyclins in lymphocytes. Cytometry A 2005; 63; 1-9.
5. Lazzereschi D, Sambuco L, Carnovale Scalzo C et al. Cyclin D1 and cyclin E expression in malignant thyroid cells and in human thyroid carcinomas. Int. J. Cancer 1998; 76; 806-811.
6. Ratschiller D, Heighway J, Gugger M et al. Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J. Clin. Oncol. 2003; 21; 2085-2093.
7. Comstock CE, Revelo MP, Buncher CR, Knudsen KE. Impact of differential cyclin D1 expression and localisation in prostate cancer. Br. J. Cancer 2007; 96; 970-979.
8. Diehl JA. Cycling to cancer with cyclin D1. Cancer Biol. Ther. 2002; 1; 226-231.
9. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Cyclin D1: normal and abnormal functions. Endocrinology 2004; 145; 5439-5447.
10. Pignataro L, Pruneri G, Carboni N et al. Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma. J. Clin. Oncol. 1998; 16; 3069-3077.
11. Yu Z, Weinberger PM, Haffty BG et al. Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin. Cancer Res. 2005; 11; 1160-1166.
12. Hui AM, Li X, Shi YZ, Takayama T, Torzilli G, Makuuchi M. Cyclin D1 overexpression is a critical event in gallbladder carcinogenesis and independently predicts decreased survival for patients with gallbladder carcinoma. Clin. Cancer Res. 2000; 6; 4272-4277.
13. Jin M, Inoue S, Umemura T et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 2001; 34; 207-218.
14. Dhar KK, Branigan K, Parkes J et al. Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells. Br. J. Cancer 1999; 81; 1174-1181.
15. Holland TA, Elder J, McCloud JM et al. Subcellular localisation of cyclin D1 protein in colorectal tumours is associated with p21(WAF1/CIP1) expression and correlates with patient survival. Int. J. Cancer 2001; 95; 302-306.
16. Lebe B, Sagol O, Ulukus C et al. The importance of cyclin D1 and Ki67 expression on the biological behavior of pancreatic adenocarcinomas. Pathol. Res. Pract. 2004; 200; 389-396.
17. Pickett CA, Agoff SN, Widman TJ, Bronner MP. Altered expression of cyclins and cell cycle inhibitors in papillary thyroid cancer: prognostic implications. Thyroid 2005; 15; 461-473.
18. Sato Y, Itoh F, Hareyama M et al. Association of cyclin D1 expression with factors correlated with tumor progression in human hepatocellular carcinoma. J. Gastroenterol. 1999; 34; 486-493.
19. Tut VM, Braithwaite KL, Angus B, Neal DE, Lunec J, Mellon JK. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. Br. J. Cancer 2001; 84; 270-275.
20. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur. J. Cancer 2005; 41; 858-887.
21. Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J. Urol. 2003; 169; 849-854.
22. Fleischmann A, Schobinger S, Markwalder R et al. Prognostic factors in lymph node metastases of prostatic cancer patients: the size of the metastases but not extranodal extension independently predicts survival. Histopathology 2008; 53; 468-475.
23. Fleischmann A, Schobinger S, Schumacher M, Thalmann GN, Studer UE. Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases. Prostate 2009; 69; 352-362.
24. Epstein JI, Algaba F, Allsbrook WC Jr et al. Acinar adenocarcinoma. In Eble JN, Sauter G, Epstein JI, Sesterhenn IA eds. World Health Organization classification of tumours. Pathology and genetics. tumours of the urinary system and male genital organs. Lyon: IARC Press, 2004; 162-198.
25. Sakr WA, Grignon DJ, Visscher DW, Wolman SR, Crissman JD. Evaluating the radical prostatectomy specimen, part I. J. Urol. Pathol. 1995; 3; 355-364.
26. Sobin LH, Gospodarowicz CH, Wittekind C eds. TNM classification of malignant tumours, 7th edn. New York: Wiley-Liss, 2009.
27. Nocito A, Kononen J, Kallioniemi OP, Sauter G. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int. J. Cancer 2001; 94; 1-5.
28. Liu CL, Montgomery KD, Natkunam Y et al. TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays. Mod. Pathol. 2005; 18; 1641-1648.
29. Soreide K. Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research. J. Clin. Pathol. 2009; 62; 1-5.
30. Boorjian SA, Thompson RH, Siddiqui S et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J. Urol. 2007; 178; 864-871.
31. Cheng L, Pisansky TM, Ramnani DM et al. Extranodal extension in lymph node-positive prostate cancer. Mod. Pathol. 2000; 13; 113-118.
32. Daneshmand S, Quek ML, Stein JP et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J. Urol. 2004; 172; 2252-2255.
33. Engel J, Bastian PJ, Baur H et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur. Urol. 2010; 57; 754-761.
34. Messing EM, Manola J, Yao J et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006; 7; 472-479.
35. Palapattu GS, Allaf ME, Trock BJ, Epstein JI, Walsh PC. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup. J. Urol. 2004; 172; 1860-1864.
36. Zwergel U, Lehmann J, Wullich B et al. Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. J. Urol. 2004; 171; 1128-1131.
37. Aaltomaa S, Eskelinen M, Lipponen P. Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival. Prostate 1999; 38; 175-182.
38. Aaltomaa S, Karja V, Lipponen P et al. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy. Anticancer Res. 2006; 26; 4873-4878.
39. Montironi R, Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Mikuz G. Prostate carcinoma I: prognostic factors in radical prostatectomy specimens and pelvic lymph nodes. BJU Int. 2006; 97; 485-491.
40. Alao JP, Gamble SC, Stavropoulou AV et al. The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines. Mol. Cancer 2006; 5; 1-11.
41. Sumrejkanchanakij P, Tamamori-Adachi M, Matsunaga Y, Eto K, Ikeda MA. Role of cyclin D1 cytoplasmic sequestration in the survival of postmitotic neurons. Oncogene 2003; 22; 8723-8730.
42. Diehl JA, Sherr CJ. A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase. Mol. Cell. Biol. 1997; 17; 7362-7374.
43. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 2006; 25; 1620-1628.
44. Comstock CE, Augello MA, Benito RP et al. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin. Cancer Res. 2009; 15; 5338-5349.
45. Cabanillas R, Rodrigo JP, Astudillo A, Dominguez F, Suarez C, Chiara MD. P53 expression in squamous cell carcinomas of the supraglottic larynx and its lymph node metastases: new results for an old question. Cancer 2007; 109; 1791-1798.
46. Harigopal M, Berger AJ, Camp RL, Rimm DL, Kluger HM. Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer. Clin. Cancer Res. 2005; 11; 4083-4089.
47. Wang Z, He YL, Cai SR et al. Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference. Int. J. Cancer 2008; 123; 1439-1447.
48. Cheng L, Leibovich BC, Bergstralh EJ et al. p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression? Cancer 1999; 85; 2455-2459.
49. Arato-Ohshima T, Sawa H. Over-expression of cyclin D1 induces glioma invasion by increasing matrix metalloproteinase activity and cell motility. Int. J. Cancer 1999; 83; 387-392.
50. Li Z, Wang C, Prendergast GC, Pestell RG. Cyclin D1 functions in cell migration. Cell Cycle 2006; 5; 2440-2442.